Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Parkinson's Disease

  Free Subscription


24.09.2018

1 Ann Neurol
1 BMC Neurol
1 Int J Neurosci
6 Mov Disord
3 Neurobiol Dis
1 Neuron
2 Neurosci Lett
1 PLoS One
1 Rev Neurol (Paris)


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Neurol

  1. SEARLES NIELSEN S, Gross A, Camacho-Soto A, Willis AW, et al
    beta2-adrenoreceptor medications and risk of Parkinson disease.
    Ann Neurol. 2018 Sep 17. doi: 10.1002/ana.25341.
    PubMed     Text format     Abstract available


    BMC Neurol

  2. VALENTINO F, Bartolotta TV, Cosentino G, Mastrilli S, et al
    Urological dysfunctions in patients with Parkinson's disease: clues from clinical and non-invasive urological assessment.
    BMC Neurol. 2018;18:148.
    PubMed     Text format     Abstract available


    Int J Neurosci

  3. LOU F, Li M, Liu N, Li X, et al
    The Polymorphism of SREBF1 Gene rs11868035 G/A Is Associated with susceptibility to Parkinson's disease in a Chinese Population.
    Int J Neurosci. 2018 Sep 20:1-18. doi: 10.1080/00207454.2018.1526796.
    PubMed     Text format     Abstract available


    Mov Disord

  4. PALACIOS N, Hughes KC, Cereda E, Schwarzschild MA, et al
    Appendectomy and risk of Parkinson's disease in two large prospective cohorts of men and women.
    Mov Disord. 2018 Sep 14. doi: 10.1002.
    PubMed     Text format     Abstract available

  5. VAN DER VELDEN RMJ, Broen MPG, Kuijf ML, Leentjens AFG, et al
    Frequency of mood and anxiety fluctuations in Parkinson's disease patients with motor fluctuations: A systematic review.
    Mov Disord. 2018 Sep 17. doi: 10.1002/mds.27465.
    PubMed     Text format     Abstract available

  6. QUATTRONE A, Barbagallo G, Cerasa A, Stoessl AJ, et al
    Neurobiology of placebo effect in Parkinson's disease: What we have learned and where we are going.
    Mov Disord. 2018;33:1213-1227.
    PubMed     Text format     Abstract available

  7. FERREIRA JJ, Trenkwalder C, Mestre TA
    Placebo and nocebo responses in other movement disorders besides Parkinson's disease: How much do we know?
    Mov Disord. 2018;33:1228-1235.
    PubMed     Text format     Abstract available

  8. SKORVANEK M, Gelpi E, Mechirova E, Ladomirjakova Z, et al
    alpha-Synuclein antibody 5G4 identifies manifest and prodromal Parkinson's disease in colonic mucosa.
    Mov Disord. 2018;33:1366-1368.
    PubMed     Text format    

  9. MESTRE TA, Ferreira JJ
    The placebo response in Parkinson's disease and other movement disorders.
    Mov Disord. 2018;33:1193-1194.
    PubMed     Text format    


    Neurobiol Dis

  10. MAMMADOVA N, Summers CM, Kokemuller RD, He Q, et al
    Accelerated accumulation of retinal alpha-synuclein (pSer129) and tau, neuroinflammation and autophagic dysregulation in a seeded mouse model of Parkinson's disease.
    Neurobiol Dis. 2018 Sep 12. pii: S0969-9961(18)30204.
    PubMed     Text format     Abstract available

  11. PINA-FUENTES D, van Zijl JC, van Dijk JMC, Little S, et al
    The characteristics of pallidal low-frequency and beta bursts could help implementing adaptive brain stimulation in the parkinsonian and dystonic internal globus pallidus.
    Neurobiol Dis. 2018 Sep 15. pii: S0969-9961(18)30391.
    PubMed     Text format     Abstract available

  12. SOYAL SM, Zara G, Ferger B, Felder TK, et al
    The PPARGC1A locus and CNS-specific PGC-1alpha isoforms are associated with Parkinson's Disease.
    Neurobiol Dis. 2018 Sep 17. pii: S0969-9961(18)30591.
    PubMed     Text format     Abstract available


    Neuron

  13. FOFFANI G, Obeso JA
    A Cortical Pathogenic Theory of Parkinson's Disease.
    Neuron. 2018;99:1116-1128.
    PubMed     Text format     Abstract available


    Neurosci Lett

  14. LU J, Chen S, Shen M, He Q, et al
    Mitochondrial regulation by pyrroloquinoline quinone prevents rotenone-induced neurotoxicity in Parkinson's disease models.
    Neurosci Lett. 2018 Sep 18. pii: S0304-3940(18)30637.
    PubMed     Text format     Abstract available

  15. CACABELOS R
    Pharmacogenomics of Alzheimer's and Parkinson's diseases.
    Neurosci Lett. 2018 Sep 17. pii: S0304-3940(18)30624.
    PubMed     Text format     Abstract available


    PLoS One

  16. LEE Y, Oh JS, Chung SJ, Lee JJ, et al
    The presence of depression in de novo Parkinson's disease reflects poor motor compensation.
    PLoS One. 2018;13:e0203303.
    PubMed     Text format     Abstract available


    Rev Neurol (Paris)

  17. BEREAU M, Fleury V, Bouthour W, Castrioto A, et al
    Hyperdopaminergic behavioral spectrum in Parkinson's disease: A review.
    Rev Neurol (Paris). 2018 Sep 14. pii: S0035-3787(18)30751.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Parkinson's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: